EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report

Yuan Gong, Hongjiang Ma, Mingyang Lu, Qiuyu Meng, Bin Liu, Tingting Yang, Haifeng Ma, Yanjun Su, Ruochuan Cheng

Frontiers in Pediatrics · 13.05.2026 · 14

DOI: 10.3389/fped.2026.1780708 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 13.05.2026. Verfasst von Yuan Gong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric papillary thyroid carcinoma (PTC) is frequently diagnosed at a locally advanced stage. Although anlotinib, an oral multi-target tyrosine kinase inhibitor (mTKI), has been employed in the treatment of locally advanced thyroid cancer (LATC) in adults, experience regarding its use in children remains limited. Case presentation A 5-year-old boy was diagnosed with LATC, characterized by extensive lymph node metastases, encasement of multiple cervical vascular structures, and distant pulmonary metastases, rendering the tumor unresectable. In accordance with a multidisciplinary team (MDT) recommendation and existing pediatric evidence, neoadjuvant therapy with oral anlotinib (8 mg/day, administered on a 2 weeks on/1 week off schedule per cycle) was initiated. No severe adverse drug reactions were observed during treatment. Following 3 cycles of neoadjuvant therapy, the tumor demonstrated sufficient regression to achieve resectability, and the patient subsequently underwent successful staged surgical resection. Permanent hypoparathyroidism was the only complication.

Methods

The patient's medical and imaging records were retrospectively analyzed. Tumor response was assessed using standardized Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and adverse events related to targeted therapy were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Conclusion

This report describes a pediatric case of LATC treated with anlotinib-based neoadjuvant therapy, which may serve as a reference for future neoadjuvant treatment approaches in children with LATC.

Schlagwörter

Stichwörter der Autor:innen

anlotinibchildrenlocally advanced thyroid carcinomaneoadjuvant therapyoncologic therapeutic regimen

Autor:innen und Institutionen

  • Department of Thyroid Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Zitieren

APA

Gong, Y., Ma, H., Lu, M., Meng, Q., Liu, B., Yang, T., Ma, H., Su, Y., & Cheng, R. (2026). Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1780708

Vancouver

Gong Y, Ma H, Lu M, Meng Q, Liu B, Yang T, et al. Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1780708

BibTeX
@article{Gong2026,
  author = {Gong, Yuan and Ma, Hongjiang and Lu, Mingyang and Meng, Qiuyu and Liu, Bin and Yang, Tingting and Ma, Haifeng and Su, Yanjun and Cheng, Ruochuan},
  title = {Neoadjuvant therapy with anlotinib in a 5-year-old child with advanced papillary thyroid carcinoma: a case report},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1780708}
}
Kostenlos starten →